MX381102B - Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. - Google Patents
Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.Info
- Publication number
- MX381102B MX381102B MX2016001384A MX2016001384A MX381102B MX 381102 B MX381102 B MX 381102B MX 2016001384 A MX2016001384 A MX 2016001384A MX 2016001384 A MX2016001384 A MX 2016001384A MX 381102 B MX381102 B MX 381102B
- Authority
- MX
- Mexico
- Prior art keywords
- benralizumab
- asthma
- treatment
- expiratory volume
- forced expiratory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 | |
| PCT/US2014/050119 WO2015023507A2 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001384A MX2016001384A (es) | 2016-08-03 |
| MX381102B true MX381102B (es) | 2025-03-12 |
Family
ID=52448838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001384A MX381102B (es) | 2013-08-12 | 2014-08-07 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
| MX2021003826A MX2021003826A (es) | 2013-08-12 | 2016-01-29 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003826A MX2021003826A (es) | 2013-08-12 | 2016-01-29 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (https=) |
| EP (5) | EP3033104B1 (https=) |
| JP (4) | JP6746496B2 (https=) |
| KR (1) | KR102337599B1 (https=) |
| CN (2) | CN105451769A (https=) |
| AU (2) | AU2014306959B2 (https=) |
| BR (1) | BR112016002317A8 (https=) |
| CA (1) | CA2917603C (https=) |
| CY (2) | CY1122033T1 (https=) |
| DK (2) | DK3033104T3 (https=) |
| ES (2) | ES2866426T3 (https=) |
| HK (1) | HK1222559A1 (https=) |
| HR (2) | HRP20190920T1 (https=) |
| HU (2) | HUE043497T2 (https=) |
| LT (2) | LT3520811T (https=) |
| ME (1) | ME03403B (https=) |
| MX (2) | MX381102B (https=) |
| PL (2) | PL3520811T3 (https=) |
| PT (2) | PT3520811T (https=) |
| RS (2) | RS58711B1 (https=) |
| RU (1) | RU2703568C2 (https=) |
| SG (1) | SG11201600483QA (https=) |
| SI (2) | SI3033104T1 (https=) |
| SM (2) | SMT201900311T1 (https=) |
| TR (1) | TR201907907T4 (https=) |
| WO (1) | WO2015023507A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| CN111617244A (zh) * | 2013-08-12 | 2020-09-04 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗改善哮喘症状的方法 |
| KR20160061352A (ko) * | 2013-10-15 | 2016-05-31 | 메디뮨 엘엘씨 | 벤랄리주맙을 사용하여 만성 폐쇄성 폐 질환을 치료하는 방법 |
| SI3060229T1 (sl) | 2013-10-24 | 2021-11-30 | Astrazeneca Ab | Stabilne vodne formulacije protiteles |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| WO2026053166A1 (en) * | 2024-09-06 | 2026-03-12 | Medimmune Limited | Anti-il5r-alpha treatment for acute exacerbations of asthma and copd |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1241944C (zh) | 1995-09-11 | 2006-02-15 | 协和发酵工业株式会社 | 抗人白介素－5受体α链的抗体 |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| US7404953B2 (en) | 2000-02-15 | 2008-07-29 | Kyowa Hakko Kogyo Co., Ltd. | Methods using eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| WO2007041635A2 (en) | 2005-10-03 | 2007-04-12 | Xencor, Inc. | Fc variants with optimized fc receptor binding properties |
| HUE036885T2 (hu) | 2007-05-14 | 2018-08-28 | Astrazeneca Ab | Eljárás a bazofil-szint csökkentésére |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| TWI732259B (zh) * | 2010-12-16 | 2021-07-01 | 美商建南德克公司 | 關於th2抑制作用之診斷及治療 |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| EP2710370A4 (en) | 2011-05-18 | 2015-01-07 | Medimmune Llc | METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS |
| HK1201440A1 (en) | 2011-11-01 | 2015-09-04 | Medimmune, Llc | Methods for reducing the frequency and severity of acute exacerbations of asthma |
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| CN111617244A (zh) * | 2013-08-12 | 2020-09-04 | 阿斯特拉捷利康股份公司 | 使用贝那利珠单抗改善哮喘症状的方法 |
-
2014
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en not_active Withdrawn
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
- 2014-08-07 EP EP25191983.3A patent/EP4636400A3/en active Pending
- 2014-08-07 SM SM20190311T patent/SMT201900311T1/it unknown
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2014-08-07 EP EP25150773.7A patent/EP4579236A3/en active Pending
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active Active
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en not_active Ceased
- 2014-08-07 SM SM20210152T patent/SMT202100152T1/it unknown
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 MX MX2016001384A patent/MX381102B/es unknown
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
-
2019
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108997A patent/JP2024129140A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| MX381102B (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| JOP20180104B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| PY1337526A (es) | Métodos para tratar o prevenir asma administrando un antagonista de IL-4R. | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| EA201690561A1 (ru) | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| MX376183B (es) | Composiciones para el tratamiento de rosacea. | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| EA201692518A3 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. | |
| MX386151B (es) | Uso de tricostatina a (tsa) en el tratamiento del mieloma múltiple. |